DENVER, Colo. (www.247marketnews.com)– These names stand out for very different reasons: NeOnc Technologies (NASDAQ:NTHI), Hyperfine (NASDAQ:HYPR), bioAffinity Technologies (NASDAQ:BIAF), Profound Medical (NASDAQ:PROF), Wolfspeed (NYSE: WOLF) and Sunshine Biopharma (NASDAQ:SBFM).
NeOnc Technologies Holdings: Big Survival Signal in Brutal Cancer Setting
NeOnc (NASDAQ:NTHI) is attacking one of the toughest corners of oncology: recurrent or progressive high-grade IDH1-mutant glioma. Its intranasal NEO100 program produced a potentially important signal in a 24-patient Phase 2a study, with median overall survival of 26.09 months measured from the first treatment dose after recurrence. Six-month progression-free survival was 48.9% under RANO 2.0 versus a prespecified 20% benchmark, with a reported p-value of 0.0047.
The delivery method is part of the story. NEO100 is administered intranasally at home and is designed to reach the brain through the olfactory pathway, potentially bypassing one of the central challenges in CNS drug development: the blood-brain barrier. NeOnc reported no major toxicities in the Phase 2a cohort, with adverse events predominantly low grade. The company believes the results are a powerful validation of the science behind NEO100.
NeOnc said it intends to engage the FDA regarding a registrational development path.
Hyperfine: Portable MRI Is Strengthening Business
Hyperfine (NASDAQ:HYPR) is increasingly making the case that portable brain MRI can become a scalable commercial category rather than simply an impressive piece of medical technology. The company expects preliminary third-quarter 2026 revenue of approximately $6.0 million, representing 53% sequential growth. More strikingly, quarterly revenue is expected to exceed net cash burn for the first time.
CEO Maria Sainz said the preliminary results demonstrate that “execution of our commercial strategy is driving meaningful growth,” citing new and follow-on health-system orders, expansion across hospital sites of care, adoption in office-based, wellness and mobile settings, and the international rollout of the Model 2 Swoop system. Management has reaffirmed full-year 2026 revenue guidance of approximately $20 million to $22 million.
The financial story still carries risk: Hyperfine expects approximately $37.9 million in cash and cash equivalents at September 30 and continues to forecast full-year net cash burn of $26 million to $28 million, but the direction is what makes the story compelling. A growing installed base, expanding international reach and improving cash discipline could give investors a clearer picture of whether Swoop can become a durable medtech franchise.
bioAffinity Technologies: AI Lung Diagnostics Gets Japanese Patent Boost
bioAffinity Technologies (NASDAQ:BIAF) is building intellectual-property protection around CyPath Lung at the same time that physicians are increasingly using the diagnostic. The Japan Patent Office issued a Notice of Allowance covering a method of predicting the likelihood of lung cancer using CyPath Lung, which combines flow cytometry with a proprietary AI-built algorithm. If issued after payment of the required fee, the patent would add another layer to the company’s international protection.
The commercial numbers provide another reason to watch. CyPath Lung test volume increased 216% year over year during the second quarter of 2026, while the company reported a 122% increase in physician offices and clinics ordering the test. Management has also been expanding the potential addressable market, including work involving surveillance of lung cancer survivors and potential diagnostic applications in asthma and COPD, and stated that the company’s commercial strategy was gaining significant traction.
The international patent strategy could become increasingly important if test adoption continues to expand. The Japanese development follows other Asian intellectual-property wins, including protection in China and Hong Kong.
Profound Medical: The MRI-Guided Surgery Story Is Getting Real
Profound Medical (NASDAQ:PROF) may be entering a new phase as its TULSA-PRO platform moves deeper into commercial adoption. The company expects third-quarter 2026 revenue of $9.8 million to $10.0 million, representing approximately 85% to 89% year-over-year growth and roughly 292% to 300% sequential growth from the second quarter. Gross margin is expected to exceed 70%, while preliminary revenue is dramatically above the company’s $2.5 million Q2 figure.
“The significant increase in revenue we expect to report this quarter represents a historic milestone for Profound,” CEO and Chairman Arun Menawat said. Management has attributed the growth to increased commercial activity across the installed base and new customer accounts. Earlier in the year, Profound reported 84 TULSA-PRO systems installed and a qualified sales pipeline of approximately $70 million for TULSA-PRO and Sonalleve.
The commercial momentum is being accompanied by clinical and reimbursement developments. Profound has reported results from its CAPTAIN randomized post-market study comparing TULSA with robotic radical prostatectomy, while Humana began covering the TULSA Procedure and Johns Hopkins Medicine treated its first commercial TULSA-PRO patient.
Wolfspeed: $1.5 Billion Government-Backed Chip Bet
Wolfspeed (NYSE:WOLF) landed one of the most dramatic financing catalysts in this group: a conditional commitment for up to $1.5 billion of long-term financing from the U.S. Department of War’s Office of Strategic Capital. The proposed facility would support domestic silicon carbide and wide-bandgap semiconductor production, with applications spanning defense, communications, electronic warfare, aerospace and other strategic markets.
The proposed financing could also support GaN epitaxy, GaN-on-SiC RF technology and radiation-hardening capabilities. Wolfspeed’s recent operating story adds another piece: AI data-center revenue more than doubled year over year in fiscal 2026, according to the company.
Sunshine Biopharma: Fresh Capital Meets High-Risk Pipeline
Sunshine Biopharma (NASDAQ:SBFM) is putting new money behind a business that combines a growing generic-drug portfolio with a much more speculative proprietary pipeline. The company priced a public offering expected to generate approximately $6.0 million in gross proceeds, before fees and expenses. The transaction includes common units or pre-funded units and two Series D warrants per unit, with the warrants immediately exercisable at an initial exercise price of $0.66 and expiring five years after issuance.
The financing provides working capital for a company that says it currently has dozens of generic prescription products in the Canadian market, with additional launches planned. Sunshine is also developing K1.1 mRNA, an LNP-encapsulated mRNA program targeting liver cancer, and SBFM-PL4, a protease inhibitor being investigated for SARS coronavirus infections.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.